Therapy Areas: AIDS & HIV
Gilead Touts Positive Biktarvy Results Demonstrates High Efficacy for a Broad Range of People Initiating Treatment for HIV, Including Those with HBV Coinfection
29 July 2022 - - US-based biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) has posted results reinforcing Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) as a highly efficacious treatment option for a broad range of people with HIV, including individuals with HIV/hepatitis B coinfection, the company said.

Interim data from the ALLIANCE trial evaluating Biktarvy in adults with HIV/HBV coinfection who were initiating therapy show potential suppression of HBV and HIV suppression comparable to an alternative HIV regimen.

Additionally, five-year data from two Phase 3 trials further demonstrated Biktarvy's sustained efficacy, safety profile and high barrier to resistance in adults with HIV initiating therapy.

The data were presented at the 24th International AIDS Conference (AIDS 2022).

Data from the ALLIANCE trial, which is an ongoing Phase 3 trial evaluating Biktarvy versus dolutegravir 50 mg + emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg, F/TDF, DTG+F/TDF, demonstrated the efficacy of both antiretroviral regimens, in adults with HIV/HBV co-infection initiating treatment.

The Week 48 results show Biktarvy demonstrated superior HBV DNA suppression. Importantly, participants who initiated treatment with Biktarvy versus DTG+F/TDF demonstrated superior HBV DNA suppression (


Related Headlines